

## **HREC decision to not approve Phase I Clinical Trial**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the company**”) has been informed by the Human Research Ethics Committee (HREC) it rejected the Company’s planned Phase I Clinical Trial for EmtinB™.

In making its decision, HREC determined that at this stage the supporting documentation did not sufficiently address the risk-benefit profile to justify the conduct of the planned Phase I Clinical Trial.

The HREC decision to not approve the Phase I Clinical Trial was unexpected and the Company is seeking clarification on the rationale for the decision to determine what steps can be taken to proceed with the Phase I Clinical Trial.

The market will be updated when more information is available.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Matthew Liddelow  
CEO and Managing Director  
ml@neuroscientific.com  
+ 61 8 6382 1805

### **About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

### **About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.